Monimus Capital Management LP Takes Position in Codexis, Inc. (NASDAQ:CDXS)

Monimus Capital Management LP purchased a new stake in Codexis, Inc. (NASDAQ:CDXS) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 71,050 shares of the biotechnology company’s stock, valued at approximately $339,000. Monimus Capital Management LP owned approximately 0.09% of Codexis as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Intech Investment Management LLC bought a new position in Codexis in the 3rd quarter valued at approximately $66,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Codexis during the 4th quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Codexis during the 4th quarter worth approximately $82,000. Jackson Square Capital LLC acquired a new stake in shares of Codexis during the 4th quarter worth approximately $210,000. Finally, GSA Capital Partners LLP grew its position in shares of Codexis by 83.5% during the 3rd quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock worth $307,000 after buying an additional 45,337 shares during the period. Institutional investors and hedge funds own 78.54% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price objective on shares of Codexis in a research note on Friday, November 22nd.

Codexis Stock Up 9.9 %

CDXS stock opened at $2.78 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $230.29 million, a PE ratio of -3.20 and a beta of 2.12. Codexis, Inc. has a twelve month low of $2.47 and a twelve month high of $6.08. The stock has a 50-day simple moving average of $4.11 and a two-hundred day simple moving average of $3.94.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The business had revenue of $21.46 million for the quarter, compared to analysts’ expectations of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. On average, equities analysts predict that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.